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RESUMO
Introdução: A ressonância magnética é considerada o exame complementar mais importante para o diagnóstico de esclerose múltipla, 
seus diagnósticos diferenciais e avaliação da sua progressão/resposta terapêutica. No entanto, para um uso ótimo desta ferramenta 
na esclerose múltipla, é essencial a aplicação de um protocolo de imagem padronizado, reprodutível e comparável. Neste contexto, 
o Grupo de Estudos de Esclerose Múltipla e a Sociedade Portuguesa de Neurorradiologia, após discussão conjunta, designaram um 
comité de peritos para a criação de recomendações adaptadas à realidade nacional sobre a utilização da ressonância magnética na 
esclerose múltipla. Este documento corresponde à segunda parte das primeiras recomendações de consenso portuguesas sobre a 
utilização da ressonância magnética na esclerose múltipla na prática clínica.
Material e Métodos: O Grupo de Estudos de Esclerose Múltipla e a Sociedade Portuguesa de Neurorradiologia após discussão do 
tema em reuniões de âmbito nacional e de uma reunião do grupo de trabalho que teve lugar na Figueira da Foz em maio de 2017, 
designaram um comité de peritos que elaboraram por método de consenso protocolos padronizados sobre o uso da ressonância 
magnética na esclerose múltipla. O documento teve como base a melhor evidência científica e a opinião dos peritos. Posteriormente, 
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ABSTRACT
Introduction: Magnetic resonance imaging is recognized as the most important diagnostic test in the diagnosis of multiple sclerosis, 
differential diagnosis and evaluation of progression/therapeutic response. However, to make optimal use of magnetic resonance im-
aging in multiple sclerosis, the use of a standard, reproducible and comparable imaging protocol is of uttermost importance. In this 
context, the Portuguese Society of Neuroradiology and the Group of Studies of Multiple Sclerosis, after a joint discussion, appointed a 
committee of experts to create recommendations adapted to the national reality on the use of magnetic resonance imaging in multiple 
sclerosis. This document represents the second part of the first Portuguese consensus recommendations on the use of magnetic reso-
nance imaging in multiple sclerosis in clinical practice.
Material and Methods: The Portuguese Society of Neuroradiology and the Group of Studies of Multiple Sclerosis, after discussing the 
topic in national meetings and after a working group meeting held in Figueira da Foz, May 2017, appointed a committee of experts that 
have developed several standard protocols on the use of magnetic resonance imaging on multiple sclerosis by consensus. The docu-
ment obtained was based on the best scientific evidence and expert opinion. Portuguese multiple sclerosis consultants and depart-
ments of neuroradiology scrutinized and reviewed the consensus paper; comments and suggestions were considered. Standardized 
strategies of magnetic resonance imaging referral in clinical practice for diagnosis and follow-up of multiple sclerosis were published 
in the first part of this paper.
Results: We provide magnetic resonance imaging acquisition protocols regarding multiple sclerosis diagnostic and monitoring and the 
information to be included in the report for application across Portuguese healthcare institutions.
Conclusion: We hope that these first Portuguese magnetic resonance imaging guidelines will contribute to optimize multiple sclerosis 
management and improve patient care in Portugal.
Keywords: Demyelinating Diseases; Magnetic Resonance Imaging; Multiple Sclerosis; Practice Guidelines as Topic
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o documento foi enviado para escrutínio à maioria dos responsáveis de consulta de esclerose múltipla e dos departamentos de neu-
rorradiologia; tendo sido considerados os seus comentários e sugestões. As estratégias padronizadas de referenciação imagiológica 
na prática clínica para o diagnóstico e seguimento da esclerose múltipla foram publicadas na primeira parte deste artigo.
Resultados: Neste artigo são propostos os protocolos de aquisição de ressonância magnética adequados para o diagnóstico e moni-
torização da esclerose múltipla, bem como a informação a constar do relatório imagiológico, tendo em vista a sua aplicação nas várias 
instituições de saúde portuguesas. 
Conclusão: Os autores esperam que estas primeiras orientações portuguesas sobre a utilização da ressonância magnética na escle-
rose múltipla na prática clínica contribuam para otimizar a gestão desta patologia e melhorar o tratamento destes doentes em Portugal.
Palavras-chave: Doenças Desmielinizantes; Esclerose Múltipla; Protocolos; Ressonância Magnética 
INTRODUCTION
 Since the first formal inclusion of magnetic resonance 
imaging (MRI) in multiple sclerosis (MS) diagnostic criteria 
in 2001,1 we have witnessed significant imaging advances 
and widespread clinical implementation. MRI is presently 
the most important diagnostic test in the diagnosis of MS, 
differential diagnosis and to evaluate MS dissemination in 
space and/or time. MRI is a fundamental tool for monitor-
ing therapeutic response and depicting t adverse effects of 
treatment. 
 MRI accuracy in detecting MS plaques and in differ-
entiating these from other mimickers depends on the MR 
protocols and specific technical parameters. This is even 
more critical for monitoring response to therapy and to de-
termine progression of clinically silent disease. The use of 
a standard, reproducible and comparable imaging protocol 
with satisfactory image quality between serial studies is of 
uttermost importance to guide the management of MS pa-
tients.
 The purpose of this document, based on the profession-
al experience and the best scientific evidence available, is to 
present the first Portuguese consensus recommendations 
of an MS MR imaging protocol, for nationwide implementa-
tion. These recommendations are aimed at making better 
initial diagnoses as well as reliable imaging comparisons 
during follow-up, in the clinical practice setting. A structured 
neuroimaging report for MS, using a universal language 
with clinical appropriateness, will also be presented. 
 
MATERIAL AND METHODS
 The Portuguese Society of Neuroradiology-forum 
(SPNR-forum) and the Grupo de Estudos de Esclerose 
Múltipla (GEEM, the main Portuguese healthcare profes-
sionals group dedicated to MS study and treatment), sup-
ported by the Portuguese Neurological Society, nominated 
among their respective members a group of experts, origi-
nating from academic and community-based MS centers, to 
convey and write the first draft of a consensus, based on the 
best available scientific evidence and clinical expertise. 
 The SPNR-forum initiated its activity in 2016 by revising 
the recently published scientific evidence, integrated with 
the clinical expertise and available advances in imaging 
technology, to define standardized MR protocols for diagno-
sis and monitoring of MS in order to implement them nation-
wide in imaging departments/institutions. 
 The SPNR-forum and the GEEM nominated a working 
group to develop the first Portuguese National recommen-
dations for the use of the magnetic resonance imaging in 
multiple sclerosis in clinical practice. After several discus-
sions about the topic in national meetings and after a work-
ing group meeting held in Figueira da Foz, in May 2017, a 
standard protocol on the use of MRI in MS was developed 
by consensus. The document obtained was based on the 
best scientific evidence and expert opinion. Subsequently, 
in order to generate a broader agreement and evaluation 
of ease of implementation, the majority of Portuguese MS 
consultants and departments of neuroradiology scrutinized 
and reviewed the consensus paper - comments and sug-
gestions were considered. Timing and frequency of investi-
gations, and other considerations such as MS criteria, were 
addressed in a separate paper.2
RESULTS
Generic practical aspects of MRI protocols implemen-
tation
 High-field MR imaging improves MS characterization, in-
creasing lesion load quantification both on T2 weighted fluid 
attenuation inversion recovery (T2-FLAIR) and gadolinium-
enhanced T1 weighted sequence and having a greater cor-
relation with physical disability and cognitive measures.3,4 
In patients with clinical isolated syndrome (CIS), the higher 
lesion load in 3T MRI units influenced the imaging classi-
fication of dissemination in space (but not in time) on first 
McDonald criteria.5 Until now, it has not been proved that 
the use of higher fields results in earlier diagnosis and we 
must consider that most Portuguese imaging centres are 
equipped with 1.5T scanners.
 The application of advanced techniques in high-field 
and ultra-high-field scanners, such as susceptibility weight-
ed imaging (SWI) and double-inversion recovery (DIR) may 
put in evidence characteristic features of multiple sclerosis 
plaques such as the perivenular distribution and cortical 
involvement, respectively, improving diagnostic specificity 
(see above). 
 The consensus recommendation is that it is mandatory 
to perform multiple sclerosis imaging at least in 1.5T MR 
unit. If the institution has a 3T MR scanner available, this 
may be preferably used, especially for brain imaging, but 
what is crucial is to guarantee that follow-up studies will be 
performed on the same magnetic field to allow an accurate 
comparison.
 Regarding the spinal cord, the use of magnetic fields 
higher than 1.5T adds no diagnostic or prognostic value. 
Instead, the increase of B0 generates more Gibbs artefacts 
and movement artefacts, from cerebrospinal fluid (CSF) 
pulsation and breathing, inducing false positives. It also 
results in higher energy deposit and consequent higher 
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specific absorption rate, which can be partially compensat-
ed by fast parallel imaging.  
 All brain must be covered with axial slices, which should 
be oriented parallel to the subcallosal line, both on 2D se-
quences and 3D sequences reformations. Precise and con-
sistent repositioning is fundamental for longitudinal evalua-
tion of disease progression across time. 
 We recommend non-gapped slice thickness of ≤ 3 mm 
and in-plane spatial resolution of 1 x 1 mm for brain studies. 
 For the spinal cord, sequences in sagittal planes should 
be performed with non-gapped slice thickness of ≤ 3 mm 
and in axial planes with non-gapped slice thickness of ≤ 5 
mm.
Recommendations summary 
Generic practical aspects of MRI protocols 
implementation
• Mandatory: Multisequence MRI must be 
performed at magnetic field strength of at least 
1.5T or higher.
• Highly recommended: Brain MR imaging should 
have non-gapped slice thickness of ≤ 3 mm and 
in-plane spatial resolution of 1x1mm for brain 
studies. 
• Highly recommended: Spinal cord sequences in 
sagittal planes should be performed with non-
gapped slice thickness of ≤ 3 mm and in axial 
planes with non-gapped slice thickness of ≤ 5 
mm.
MRI protocols for diagnosis and follow-up
 1. Brain imaging protocol
 Brain MRI scan is essential in order to make an accurate 
diagnosis of MS, as well as monitoring disease activity and 
treatment efficacy and/or adverse effects. However, its sen-
sitivity directly depends on a standardized imaging protocol, 
which includes at least two T2-weighted sequences on the 
axial plane, a sagittal T2-FLAIR and a contrast-enhanced 
T1-weighted sequence, acquired with non-gapped slice 
thickness of ≤ 3 mm and in-plane spatial resolution of 1 x 1 
mm. Additional sequences might complement the informa-
tion given by the brain MRI, namely in differential diagnosis 
and detection of treatment adverse effects, as discussed 
further. The protocol for brain MRI is summarized in Table 1. 
 1.1 Proton Density (PD) / T2 WI and T2-FLAIR/DF 
 T2 weighted imaging (WI) sequences are imperative 
in multiple sclerosis both for diagnosis and follow-up. This 
should be acquired with a non-gapped slice thickness of ≤ 3 
mm and in-plane spatial resolution of 1 x 1 mm. T2 and pro-
ton-density have better sensitivity for infra-tentorial lesions, 
while T2-FLAIR allows better detection of periventricular 
and juxtacortical lesions. In particular, sagittal T2-FLAIR is 
useful to characterize disease affecting the corpus callosum 
and to demonstrate the ovoid morphology of perivenular 
lesions (‘Dawnson fingers’). Additionally, in areas particu-
larly susceptible to artefacts, such as temporal poles and 
posterior fossa, we must confirm the presence of a demy-
elinating lesion in two T2-weighted sequences. Therefore, 
we recommend axial planes of conventional spin-echo or 
fast spin-echo T2 and proton-density (acquired with a dual 
echo) and/or T2-FLAIR, combined with sagittal T2-FLAIR.
 We highly recommend acquiring a 3D T2-FLAIR/dark 
fluid (DF) (1 mm3 isotropic voxel) followed by multiplanar 
reconstructions on the axial plane with slice thickness of 3 
mm without gap. The advantages of using a 3D T2-FLAIR 
include: more homogenous CSF suppression, important 
reduction of CSF and blood flow artefacts, and increased 
posterior fossa lesion detection (equal or superior to T2-
weighted6). Post-processing flexibility, including longitudinal 
co-registration for subtraction images and automated lesion 
segmentation, is an additional advantage.
 We also suggest the use of coronal T2 FAT-SAT/ short 
tau inversion recovery (STIR) for optic nerve evaluation in 
case of optic neuritis clinical suspicion.   
Recommendations summary 
MRI protocols for diagnosis and follow-up
(PD / T2 WI and T2-FLAIR/DF) 
• Mandatory: It is mandatory to include an axial 
T2 and proton-density, combined with a sagittal 
T2-FLAIR/DF. 
• Highly recommended: It is highly recommended 
to use a 3D T2-FLAIR/DF instead of sagittal and 
axial T2-FLAIR. 
• Optional: We suggest that coronal T2 FAT-SAT / 
STIR should be used for optic nerve evaluation 
if optic neuritis is suspected.
 1.2 T1 weighted and contrast-enhanced 
 At 1.5T it is well established that conventional 2D 
spin-echo sequences are more sensitive for identification 
of active MS lesions enhanced with gadolinium. Axial T1 
spin-echo images should be acquired with a non-gapped 
slice thickness of ≤ 3 mm and in-plane spatial resolution 
Table 1 – Protocol for brain MRI at baseline and follow up)
Brain MRI 
Mandatory sequences
Axial T2 axial
Axial PD and/or T2-FLAIR axial
Sagittal T2-FLAIR (2D or 3D)
Axial T1 SE 2D + gad 
Optional sequences
Axial T1 SE 2D 
3D T1-weighted sequences (particularly at 3T)
Axial DWI 
DIR
SWI
Non-gapped slice thickness of ≤ 3 mm and in-plane spatial 
resolution of 1x1mm.
Gadolinium (single dose: 0,1 mmol/kg body weight) must 
be injected at least 5 minutes prior to T1 acquisition - we 
suggest injection before FLAIR to save time.
Pereira DJ, et al. First Portuguese consensus recommendations for the use of magnetic resonance imaging in MS, Acta Med Port 2020 Jan;33(1):66-75
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of 1 x 1 mm.
 The paradigm has been changing with technical devel-
opments including the wide implementation of single-slab 
3D images, parallel imaging in higher field strengths, to-
gether with better receiver coil arrays and gradients.  The 
higher field strength of 3T MRI scanners improves image 
resolution, allowing better detection of small lesions, and 
increases T1 shortening effect with gadolinium and higher 
detection rates of MS lesions compared to conventional 2D 
spin-echo at 3T.7 Also, 3D-GRE is less susceptible to pulsa-
tile flow artefacts than 2D spin-echo. Other advantages of 
including a 3D-T1 sequence in the MS protocol are easier 
comparison on follow-up and possible co-registration of lon-
gitudinal studies with subtraction image, atrophy measure 
on T1 pre-contrast study (which ideally should be the same 
sequence as the post-contrast) and improved classification 
of cortical lesions.8 Also, we can obtain high-quality images 
at any plane by reformatting the generated data set. 
 Contrast administration is mandatory whenever lesions 
are detected on T2-weighted sequences, at least in the ini-
tial study to demonstrate dissemination in time. Gadolinium 
enhancing traduces breakdown of the blood-brain barrier 
caused by inflammatory activity, distinguishing chronic le-
sions from acute new lesions, in which enhancement may 
persist from three weeks to three months.6 The recom-
mendation is a standard dose of gadolinium (single dose: 
0,1mmol/kg body weight) with a minimum delay of five min-
utes before acquisition.9 This time should be used to per-
form other sequences, namely T2/DP and/or T2-FLAIR, so 
that the total acquisition time is not extended. 
 In accordance with recent European Medicines Agency 
(EMA) recommendations,10 the use of gadolinium is now re-
stricted to macrocyclic agents (gadobutrol, gadoteric acid 
and gadoteridol). These restrictions followed the emer-
gence of several studies proving gadolinium deposition in 
brain tissues (see Gulani et al11 for a recent review) after 
the first description in 201412 of a relationship between cu-
mulative dose of gadolinium and hyperintensity of dentate 
nucleus and globus pallidus. The Food and Drug Adminis-
tration (FDA)13 also states “health care professionals should 
limit gadolinium-based contrast agents (GBCA) use to cir-
cumstances in which additional information provided by the 
contrast agent is necessary, and assess the necessity of 
repetitive MRIs with GBCAs.” Given these recent concerns, 
even though no data exists proving biological or neuro-
logical consequences from brain deposition of gadolinium, 
we should reconsider the administration of gadolinium as 
standard in follow up studies in multiple sclerosis. We can 
define disease activity by detecting new T2 lesions, al-
though gadolinium administration improves sensitivity. The 
risk-benefit ratio in this group of patients must be cautiously 
evaluated. In a patient without clinical relapses or new MRI 
lesions for the last five years it may be reasonable to per-
form follow up studies without contrast administration.14,15 
However, this aspect is still a matter of debate in the radiol-
ogy community. 
 
Recommendations summary 
MRI protocols for diagnosis and follow-up 
(T1 weighted and contrast-enhanced) 
• Mandatory: It is mandatory to acquire a 
conventional 2D T1 spin-echo after gadolinium 
injection (single dose: 0,1 mmol/kg body weight) 
with a minimum delay of 5 minutes. Isotropic 3D 
T1-weighted sequences are an equivalent and 
valuable option in 3T scanners. 
• Optional: We suggest that a conventional 2D T1 
spin-echo before gadolinium injection should 
be obtained to facilitate MS lesion enhancement 
depiction. 
 
 1.3 Diffusion-weighted imaging
 Axial diffusion-weighted imaging (DWI) (≤ 5 mm) is 
mandatory in the imaging follow up for progressive multifo-
cal leukoencephalopathy (PML) surveillance, a potentially 
devastating complication of therapy with natalizumab. PML 
is an opportunistic infection due to the reactivation and 
replication of the John Cunningham virus (JCV). There-
fore, patients with detectable JCV serum antibodies are at 
higher risk and should follow a PML-surveillance algorithm 
described in the first part of these consensus recommen-
dations.2 MRI has high sensitivity in the detection of PML 
lesions months before the first symptoms, and it has been 
shown that those patients that were asymptomatic at the 
time of PML diagnosis had less functional disability and 
higher survival.16 DWI hyperintensity is considered a very 
helpful feature for diagnosing PML,17 reflecting acute de-
myelination with consequent swelling of oligodendrocytes 
and astrocytes.18 However, we should be aware that high 
signal intensity in DWI might be absent in 40% of the pre-
symptomatic patients, particularly in smaller and/or cortical 
lesions.19 
 We highly recommend the use of DWI in the core MR 
protocol of the first examination to exclude non-MS lesions, 
in particular differentiating it from acute ischemia. Indeed, 
most MS acute and chronic MS lesions have increased 
ADC values, largely due to extracellular oedema and axonal 
loss. However, in a subgroup of patients, we may also find 
hyperacute demyelinating lesions with transient diffusion re-
striction.20 DWI cannot replace gadolinium-enhanced T1WI 
for the distinction between acute and chronic lesions.21
Recommendations summary 
MRI protocols for diagnosis and follow-up 
(Diffusion-weighted imaging) 
• Mandatory: Is mandatory to obtain 2D axial DWI 
(≤5 mm) for patients with higher risk of PML
• Optional: we suggest that 2D axial DWI (≤5 mm) 
should be obtained in the initial MRI scan for 
differential diagnosis purposes.
 1.4 Optional sequences
 a) SWI and other susceptibility-based techniques
 MRI techniques susceptible to iron in deoxygenated 
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haemoglobin (SWI and T2*) made accessible in vivo the 
typical perivenous morphology of MS lesions, already 
known from histological data. This was first demonstrated 
on T2* at 7T22 and the same group proved further that this 
perivenous appearance was predictive of demyelination vs 
non-MS white matter lesions.23 In order to simultaneously 
highlight white matter lesions and veins, MR imaging con-
trast techniques were developed combining a single image 
3T-FLAIR and 7T-SWI phase data24 or T2* and FLAIR (both 
at 3T) called FLAIR*.25 This last technique was recently 
applied in a clinical dataset at 3T showing 100% of sen-
sitivity and 80% of specificity for more than 45% of ‘vein 
in lesion’, while dissemination in space (DIS) criteria had 
96% sensitivity and 40% specificity.26 The FLAIR* technique 
uses a T2*-weighted segmented echo-planar imaging (T2*-
segEPI) acquired during contrast injection (single-dose), 
using the paramagnetic properties of gadolinium to com-
pensate for the less sensitivity to susceptibility effects at 3.0 
T compared to 7.0 T.25 Furthermore, MS lesions also exhibit 
a characteristic rim or nodular low signal on susceptibility-
based sequences, which may help to differentiate CIS or 
MS from other neurological disorders.27,28 
 The inclusion of susceptibility-based techniques as an 
optional sequence on the first diagnostic may be useful for 
the differential diagnosis. 
 FLAIR* is not available in most Portuguese imaging 
centres, but is possible to have a perception of the “vein in 
lesion” by merging 3D FLAIR and SWI (Fig. 1).
 b) DIR or PSIR
 Cortical lesions are typical and abundant on MS, as 
shown by histopathological data.29 MRI techniques allow as-
sessment in vivo and characterization of grey matter pathol-
ogy in MS in such a way that cortical lesions were included 
on 2016 MAGNIMS criteria30 and on the recently revised 
McDonald criteria (2017).31 DIR is one of those sequences 
that improves the detection of cortical lesions, in this case 
by suppressing signals from white matter and CSF. On the 
other hand, DIR is susceptible to flow-related artefacts and 
variations on grey matter signal intensity, leading to fre-
quent false positives and low interobserver concordance.8,32 
 Phase-sensitivity inversion recovery (PSIR) seems to 
improve detection and classification of intracortical lesions 
when combined with DIR33, even though lesions with mini-
mal extension into the white matter still remain difficult to 
classify, even with this combined protocol. In this context, 
3D MPRAGE provides additional information to improve 
lesion classification,8 with the advantage of being widely 
available in most manufacturers without additional cost and, 
consequently, being easily implemented in clinical practice. 
 Any of these sequences may be included as optional 
on the MS protocol at 3T since cortical lesions can now be 
used to fulfil MRI criteria for DIS.31 However, they are not 
considered mandatory since we must be aware that MR ca-
pacity for detection of grey matter pathology is far below the 
gold standard of histopathology and we lack standardiza-
tion of image acquisition and image analysis of cortical le-
sions with specific imaging criteria.34 Furthermore, DIR and 
PSIR are not universally available in Portuguese imaging 
centres. 
Recommendations summary 
MRI protocols for diagnosis and follow-up  
(optional sequences) 
• Optional: SWI and DIR may be included on the 
MS protocol as optional sequences. 
 1.5 Spinal cord imaging protocol
 Spinal cord MRI imaging is prone to different types of 
artefacts, being technically challenging and sometimes dif-
ficult to interpret not only because spinal cord has a small 
cross-sectional area, which is surrounded by a high amount 
of fat, bone, CSF and vessels, but also because spinal cord 
imaging is susceptible to both participant movements and 
Figure 1 – (A) Susceptibility-weighted imaging (MIP). (B) Axial reconstruction of 3D T2-FLAIR. (C) Fused image (A+B). MS lesions tend 
to be distributed along the course of deep medullary veins, a phenomenon that can be depicted in fused SWI-FLAIR images, contributing 
to the differential diagnosis
A B C
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intrinsic motion promoted by cardiac and respiratory cycles.
 Nevertheless, spinal cord imaging significantly adds 
diagnostic and prognostic value in MS, with asymptomatic 
lesions being detected in 42% of patients with CIS.35 The 
presence of spinal cord MS lesions may also contribute to 
fulfil the 2017 McDonaldcriteria for space and time dissemi-
nation31 and to predict conversion to clinically definite MS.21 
Specific indications on the frequency and timing to perform 
spinal cord MRI were also stated in the first part of these 
guidelines2. 
 Protocol for spinal cord MRI is summarized in Table 2.
 1.5.1 T2 weighted
 Sagittal planes are the main approach in spinal cord im-
aging since they allow an extensive coverage of the cervical 
and/or dorsal segments with a reasonable acquisition time 
compared to axial planes. However, sagittal imaging is also 
more susceptible to artefacts that can easily lead to false 
positives. Conventional spin-echo or fast spin-echo T2 is 
considered the reference standard, always being part of 
the protocol. But, it is generally recognized that these con-
ventional sequences lack sensitivity and specificity for MS 
lesions.36-38 It is mandatory to complement conventional 
T2-weighted sequence with a proton-density or a STIR se-
quence (Fig. 2). STIR has a higher contrast-to-noise ratio, 
making the lesions ‘brighter’, but it is also more affected by 
flow-related artefacts, frequently leading to the identification 
of erroneous lesions. That is, compared to proton-density, 
STIR has higher sensitivity but lower specificity. 
 More recently, an alternative to STIR in the cervical seg-
ment (where flow-related artefacts become more problem-
atic) is PSIR, which has an excellent lesion-to-cord contrast 
ratio. However, it is not as widely available in our healthcare 
institutions and, although it performs slightly better than 
STIR in cervical cord,39,40 it is far less sensitive in the dorsal 
segment.40 
 In the axial plane, it is important to perform high-res-
olution sequences (pixel size ≤ 1 mm2) due to the small 
cross-sectional area of spinal cord.41,42 It is common to use 
T2-weighted gradient echo sequences with short echo time 
in order to reduce CSF flow artefacts and acquisition time, 
especially in the cervical segment. Although more time-con-
suming, thin-slice T2-weighted fast-spin echo sequences 
(2D or 3D) are also appropriate to increase detection of 
MS lesions, particularly in the dorsal segment. Axial T2 WI 
should be performed for better characterization of lesions 
suspected/detected on sagittal planes. 
 In conclusion, we can only define a spinal cord lesion if 
we detect a hyperintense area 1) in the sagittal plane both 
Figure 2 – Sagittal cervical spinal cord images. (A) T2-weighted fast spin-echo. (B) Proton-density (acquired at dual-echo). (C) Short-tau 
inversion recovery (STIR). The images depict confluent cervical lesions in an MS patient extending from C2-C3 to C6. At least two T2 
sequences are required to identify a demyelinating plaque at the spinal cord. Spinal lesions should also be confirmed on the axial plane.
A B C
Table 2 – Protocol for spinal cord MRI 
Spinal Cord MRI
Mandatory sequences
Sagittal T2 SE or FSE
Sagittal PD (acquired in dual echo) or STIR
Axial T2 (lesion focused)
Sagittal T1 SE + gad (if T2 lesions present)
Optional sequences
Sagittal T1 SE 
Axial T1 SE + gad 
Axial 2D or 3D T2 FSE (for all spinal cord)
PSIR
Non-gapped slice thickness of ≤ 3 mm in sagittal planes 
and non-gapped slice thickness of ≤ 5 mm in axial planes.
Gadolinium injection (single dose: 0,1 mmol/kg body 
weight) should be done preferably in a “one-stop-strategy”.
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on T2 and another appropriate sequence (STIR, DP, PSIR) 
or 2) if we identify it in two T2 weighted planes.31
Recommendations summary 
Spinal cord MRI imaging (T2 weighted) 
• Mandatory: It is mandatory to obtain at least two 
T2 weighted sequences in the sagittal plane, 
and they must include a conventional spin-
echo or fast spin-echo T2 plus proton-density-
weighted (acquired with a dual-echo) or short-
tau inversion recovery sequences (STIR). 
• Mandatory: If spinal cord lesions are detected 
on sagittal plane sequences, it is mandatory to 
include a focussed axial T2-weighted sequence.
 1.5.2 T1 weighted
 Only a small number of spinal cord lesions enhances 
after gadolinium administration compared with the brain 
(four to ten times more common) and are usually related 
to new clinical symptoms.21,41 We recommended acquiring 
a sagittal contrast-enhanced T1-weighted spin-echo, when 
T2 lesions are present, if possible in the same session as 
brain MRI. This will save time and reduce the number of 
gadolinium administrations and its potential adverse ef-
fects in these chronic patients (as discussed in 2.1.2). Axial 
contrast-enhanced T1-weighted spin-echo acquisition is op-
tional. 
 MS abnormalities are rarely seen on spontaneous sagit-
tal T1-weighted imaging, adding no significant value to the 
standard protocol regarding spinal cord evaluation.42 In or-
der to facilitate the lesion enhancement depiction, the ac-
quisition of a conventional (sagittal) 2D T1 spin-echo before 
gadolinium injection may be useful. 
Recommendations summary
Spinal cord MRI imaging  (T1 weighted) 
• Mandatory: It is mandatory to obtain a sagittal 
contrast-enhanced T1-weighted spin-echo 
when spinal cord MS T2 lesions are identified 
on spinal imaging.
• Highly recommended: It is highly recommended 
to follow the “one-stop-strategy”: include a 
contrast-enhanced T1-weighted spin-echo 
when brain MS T2 lesions are identified in brain 
imaging.
• Optional: We suggest that a conventional 
sagittal 2D T1 spin-echo should be obtained 
before gadolinium injection to facilitate MS 
lesion enhancement depiction. 
2. Advanced techniques
 In the past years, the great advance in acquisition and 
analysis of non-conventional MR imaging encouraged the 
publication of several MS studies using those advanced 
techniques to better characterize both the pathophysiology 
at tissular/microscopical level and the prognosis in a more 
individualized manner.
 Magnetization transfer imaging (MTI), based on the ex-
change of magnetization between pools of bound and free-
protons,43 provides quantitative metrics sensitive to neuro-
degenerative microstructural changes on MS, in contrast 
to conventional techniques that predominantly reflect the 
inflammatory aspect of the disease.44 This method is easy 
to implement in the clinical setting, but it lacks specificity, 
widely changing with biophysical parameters and between 
scanners.43,44
 Myelin-water imaging (MWI) is a multi-echo T2 re-
laxation technique that assesses water trapped in myelin 
bilayers. It quantifies the myelin content, with strong his-
topathological correlations,45 which was shown to be het-
erogeneously reduced in different MS-lesion type and even 
in normal-appearing white matter (NAWM).46 There are sev-
eral potential confounding factors that may influence this 
quantitative data and difficult MWI clinical implementation,47 
even though recent advances allowed shorter acquisition 
times and whole-brain coverage.43 
 The integrity of white matter tracts can be assessed by 
diffusion tensor imaging (DTI) and seems to be linked with 
cognitive impairment and progression of physical disabil-
ity.43
 MR spectroscopy may also contribute to the assess-
ment of axonal damage, with NAA decreases consistently 
reported, and to study grey matter pathology, nowadays 
recognized as significant in MS48. Both have unsolved tech-
nical issues that compromise reproducibility and translation 
to clinical practice.
 Perfusion, both arterial spin labelling (ASL) and dynamic 
susceptibility contrast (DSC), has produced contradictory 
results43 and has no place in routine imaging evaluation of 
MS patients (except in case of tumefactive demyelinating 
lesions, in which perfusion can be useful for differential di-
agnosis with neoplasms).49 
 Functional MRI (fMRI) has proved to be an interesting 
tool to assess adaptive cortical changes/reorganization that 
may limit the clinical impact of structural injury.50 fMRI ap-
plications are presently limited to group studies, in research 
or, eventually, clinical trials, and does not have a role in clini-
cal practice. 
 In conclusion, despite being theoretically appealing, 
most MR advanced techniques are technically complex, 
time-consuming and difficult to implement outside the re-
search framework. 
 Imaging postprocessing methods, specially automated 
methods, to measure brain atrophy progression (longitudi-
nal volumetric studies) or to perform automatic lesion count 
(including subtraction images and automatic and semiauto-
matic segmentation) may be included only as an aid to our 
imaging evaluation in clinical practice, taking into account 
that they are not formally approved yet and still have some 
limitations. In addition, neuroradiologists must have the ex-
pertise and the hospitals/imaging centres need to provide 
access to the tools demanded for this type of evaluation. 
Pereira DJ, et al. First Portuguese consensus recommendations for the use of magnetic resonance imaging in MS, Acta Med Port 2020 Jan;33(1):66-75
N
O
R
M
A
S 
O
R
IE
N
TA
Ç
Ã
O
Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                73
Pereira DJ, et al. First Portuguese consensus recommendations for the use of magnetic resonance imaging in MS, Acta Med Port 2020 Jan;33(1):66-75
Recommendations summary 
Advanced Techniques 
• Not recommended: MR advanced techniques 
(e.g. MTI, MWI, fMRI, DTI, spectroscopy or 
perfusion) lack standardization in acquisition, 
postprocessing and interpretation, not being 
recommended for routine clinical use. 
• Optional: Automated postprocessing methods 
for brain atrophy quantification and automatic 
lesion count / lesion load quantification may be 
used if available.
3. Structured Neuroimaging Report
 A concise and accurate structured neuroimaging report 
is warranted as specified in Table 3. 
 For this goal, the examination request must contain all 
the fundamental clinical information, such as a brief clinical 
history (type and duration of symptoms), the patient thera-
peutic (discrimination of the administered drugs, such as 
corticosteroids or MS-disease modifying therapy) and clini-
cal diagnostic hypothesis. If the patient performed previous 
MR imaging, the neuroradiologist must be informed and 
have access to the images and report of that examination. 
We recommend patients to have copies of their own stud-
ies in a standard readable format (DICOM), particularly if it 
is likely that they will perform the follow-up examinations in 
different imaging centres. A standard neuroimaging report 
should be adopted and divided into technical description, 
imaging reading and interpretation, with a final summary of 
the main imaging findings.
Recommendations summary 
Structured Neuroimaging Report
• Mandatory: We recommend the neuroimaging 
report to be divided into technical description, 
imaging reading and interpretation with a final 
summary of the main imaging findings (see 
Table 3).
CONCLUSION
 In these first Portuguese MRI consensus recommenda-
tions, we provide standard imaging protocols adapted to 
the Portuguese reality, based on the most recent scientific 
evidence and on our own practical experience. The harmo-
nisation of MRI protocols throughout imaging centres will 
allow a better diagnostic acuity and precise follow-up of the 
disease. Due to the great technical advances in MRI and in 
MS knowledge, these guidelines must be reviewed periodi-
cally. 
OBSERVATIONS
 The Grupo de Estudos de Esclerose Múltipla (GEEM, 
the main Portuguese healthcare professionals group dedi-
cated to MS study and treatment, supported by the Por-
tuguese Neurological Society) experts group for the first 
Portuguese Consensus Recommendations for the Use of 
the Magnetic Resonance Imaging in Multiple Sclerosis in 
Clinical Practice is composed by: Pedro Abreu, Rui Pedro-
sa, Maria José Sá, João Cerqueira, Lívia Sousa, Ana Mar-
tins da Silva, Joaquim Pinheiro, João de Sá, Sónia Batista, 
Rita Moiron Simões, José Vale.
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Table 3 – Guidelines for the neuroimaging report
Structured neuroimaging report
1. Technique  
• Magnetic field strength;
• Anatomic coverage (brain or spinal cord and which segment);
• MR sequences and planes acquired (including thickness);
• Gadolinium-based agent and dose;
• Availability and date of a previous brain and/or spinal MR 
exam for comparison.
2. Imaging findings  
• Number (count if ≥ 3 mm) and anatomical distribution of 
T2 lesions, specifying if juxtacortical/cortical, periventricular, 
infratentorial or in spinal cord;
• Subjective evaluation of lesion load (mild, moderate, severe);
• Number and anatomical distribution of gadolinium-enhancing 
T1 lesions and type of enhancement (ring, solid, concentric, 
etc.);
• Atrophy characterization with the use of validated clinical 
imaging scales, such as global cortical atrophy (GCA) scale. 
The qualitative impression of the initial atrophy and/or atrophy 
progression should be included;
• Incidental/non-MS related findings and its clinical significance ;
• Follow up: new T2 lesions, gadolinium -enhancing T1 lesions 
and increased size of previously detected MS plaques. 
3. Conclusion
• Interpret if findings are typical, atypical or not consistent with 
MS and, in this case, provide differential diagnosis;
• Indicate if MR criteria of DIS and dissemination in time (DIT) 
are fulfilled according to the 2017 MS McDonald criteria1;  
• Follow-up: conclude if there are imaging signs of new silent 
lesions or active plaques and identify potential therapeutic 
adverse effects (particularly, PML-IRIS). 
1 DIS is defined by one or more T2-hyperintense lesions in two or more of these four areas: 
periventricular, cortical/juxtacortical, infratentorial and spinal cord. DIT is demonstrated 
by: new T2 and/or gadolinium-enhancing lesion(s) on follow up MRI with reference to a 
baseline scan OR simultaneous presence of gadolinium-enhancing and non-enhancing 
lesions at any time.
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